{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:53:43Z","timestamp":1786708423816,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1124\/dmd.108.024521","type":"journal-article","created":{"date-parts":[[2008,11,13]],"date-time":"2008-11-13T01:53:52Z","timestamp":1226541232000},"page":"345-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Metabolic Activation of Benzodiazepines by CYP3A4"],"prefix":"10.1016","volume":"37","author":[{"given":"Katsuhiko","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Negishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Hashizume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.108.024521_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0022-3565(25)38106-1","article-title":"Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies","volume":"265","author":"Berson","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.024521_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0006-2952(86)90561-7","article-title":"Biochemistry of reduction of nitro heterocycles","volume":"35","author":"Biaglow","year":"1986","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.108.024521_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2174\/138920006778520606","article-title":"Bioactivation and hepatotoxicity of nitroaromatic drugs","volume":"7","author":"Boelsterli","year":"2006","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.108.024521_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/jms.1141","article-title":"Clonazepam quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry in a bioequivalence study","volume":"42","author":"Cavedal","year":"2007","journal-title":"J Mass Spectrom"},{"key":"10.1124\/dmd.108.024521_bib5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0028-3908(02)00199-5","article-title":"GABAA receptors and benzodiazepines: a role for dendritic resident subunit mRNAs","volume":"43","author":"Costa","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1124\/dmd.108.024521_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3999\/jscpt.9.251","article-title":"Pharmacokinetics studies of flunitrazepam in healthy male Japanese subjects","volume":"9","author":"Fukazawa","year":"1978","journal-title":"Jpn J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.108.024521_bib7","series-title":"Cytochrome P-450","first-page":"473","article-title":"Human cytochrome P-450 enzymes","author":"Guengerich","year":"1995"},{"key":"10.1124\/dmd.108.024521_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/10408448509037460","article-title":"Enzymatic activation of chemicals to toxic metabolites","volume":"14","author":"Guengerich","year":"1985","journal-title":"Crit Rev Toxicol"},{"key":"10.1124\/dmd.108.024521_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/tx600260a","article-title":"Applying mechanisms of chemical toxicity to predict drug safety","volume":"20","author":"Guengerich","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.024521_bib10","first-page":"133","article-title":"CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam","volume":"29","author":"Hesse","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024521_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/00498250310001657568","article-title":"Phase I and II enzyme characterization of two sources of HepG2 cell lines","volume":"34","author":"Hewitt","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.108.024521_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cbi.2005.03.036","article-title":"Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4","volume":"155","author":"Kalgutkar","year":"2005","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.108.024521_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1124\/dmd.107.014860","article-title":"Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes","volume":"35","author":"Kang","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024521_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/tx000180q","article-title":"Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission","volume":"14","author":"Kassahun","year":"2001","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.024521_bib15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/03602539409029806","article-title":"Metabolic activation of N-hydroxylated metabolites of carcinogenic and mutagenic arylamines and arylamides by esterification","volume":"26","author":"Kato","year":"1994","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.108.024521_bib16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1021\/tx00009a004","article-title":"Covalent interaction of 5-nitroimidazoles with DNA and protein in vitro: mechanism of reductive activation","volume":"2","author":"Kedderis","year":"1989","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.024521_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/03602538809049618","article-title":"The metabolic activation of nitroheterocyclic therapeutic agents","volume":"19","author":"Kedderis","year":"1988","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.108.024521_bib18","first-page":"460","article-title":"Flunitrazepam metabolism by cytochrome P450s 2C19 and 3A4","volume":"29","author":"Kilicarslan","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024521_bib19","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1096\/fasebj.13.10.1169","article-title":"Regulation of hepatic glutathione synthesis: current concepts and controversies","volume":"13","author":"Lu","year":"1999","journal-title":"FASEB J"},{"key":"10.1124\/dmd.108.024521_bib20","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1038\/sj.onc.1202581","article-title":"Caspases: the proteases of the apoptotic pathway","volume":"17","author":"Nu\u00f1ez","year":"1998","journal-title":"Oncogene"},{"key":"10.1124\/dmd.108.024521_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1124\/dmd.108.021964","article-title":"Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity","volume":"37","author":"Ohbuchi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024521_bib22","first-page":"576","article-title":"Anticonvulsant-induced liver damage","volume":"83","author":"Olsson","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/dmd.108.024521_bib23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3109\/00498259609046742","article-title":"Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and 3A subfamily","volume":"26","author":"Ono","year":"1996","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.108.024521_bib24","first-page":"195","article-title":"Metabolic basis of adverse drug reaction","volume":"20","author":"Park","year":"1986","journal-title":"J R Coll Phys Lond"},{"key":"10.1124\/dmd.108.024521_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00296939","article-title":"Activation mechanisms to chemical toxicity","volume":"60","author":"Parke","year":"1987","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.108.024521_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/15287390490264767","article-title":"NADPH-cytochrome P-450 reductase is involved in flunitrazepam reductive metabolism in HepG2 and Hep3B cells","volume":"67","author":"Peng","year":"2004","journal-title":"J Toxicol Environ Health A"},{"key":"10.1124\/dmd.108.024521_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/03602538708998299","article-title":"Metabolism of nitroaromatic compounds","volume":"18","author":"Rickert","year":"1987","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.108.024521_bib28","first-page":"1134","article-title":"Methods for estimating 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one and its principal metabolites in biological samples and results of research on the pharmacokinetics and metabolism of this compound in humans and rats","volume":"15","author":"Rieder","year":"1965","journal-title":"Arzneimittel-Forschung"},{"key":"10.1124\/dmd.108.024521_bib29","first-page":"212","article-title":"Plasma levels and derived pharmacokinetic characteristics of unchanged nitrazepam in man","volume":"23","author":"Rieder","year":"1973","journal-title":"Arzneimittel-Forschung"},{"key":"10.1124\/dmd.108.024521_bib30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/00498250210128675","article-title":"Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells","volume":"32","author":"Rodr\u00edguez-Antona","year":"2002","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.108.024521_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3565(25)27131-2","article-title":"Metabolism of diazepam in rat, dog, and man","volume":"149","author":"Schwartz","year":"1965","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.024521_bib32","series-title":"552nd Meeting for the Japanese Society of Internal Medicine Kanto Division; 2008 Mar 8; Tokyo, Japan.","first-page":"31","article-title":"Case report: severe hepatic disorder induced by chronic administration of antidepressants drugs","author":"Seki","year":"2008"},{"key":"10.1124\/dmd.108.024521_bib33","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.024521_bib34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/tx980249i","article-title":"New concepts in immunology relevant to idiosyncratic drug reactions: the \u201cdanger hypothesis\u201d and innate immune system","volume":"12","author":"Uetrecht","year":"1999","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.108.024521_bib35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.tox.2005.08.003","article-title":"An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics","volume":"216","author":"Vignati","year":"2005","journal-title":"Toxicology"},{"key":"10.1124\/dmd.108.024521_bib36","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/dmd.31.8.1035","article-title":"Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties","volume":"31","author":"Wilkening","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024521_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/dmd.30.2.155","article-title":"Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells","volume":"30","author":"Yamamoto","year":"2002","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624019445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624019445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.108.024521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:34:23Z","timestamp":1739896463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624019445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0090955624019445"],"URL":"https:\/\/doi.org\/10.1124\/dmd.108.024521","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic Activation of Benzodiazepines by CYP3A4","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.108.024521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}